For research use only. Not for therapeutic Use.
ZG-2033 is a potent and orally bioavailable hypoxia-inducible factor 2α (HIF-2α) agonist with an EC50 value of 490 nM. In the in vivo efficacy assays, the combination of ZG-2033 and the prolyl hydroxylase inhibitor, AKB-6548 (Axon 3288), was confirmed for the first time to synergistically increase the plasma erythropoietin level in and alleviate zebrafish anemia induced by doxorubicin.
KEYWORDS: ZG-2033 | Supplier | HIF-2α agonist | ZG2033 | ZG 2033 | CAS [2685739-28-8] | DNA-RNA | HIF | Agonist | Transcription Factors | Renal anemia
| Catalog Number | I047681 |
| CAS Number | 2685739-28-8 |
| Molecular Formula | C15H14N2O2S |
| Purity | ≥95% |
| IUPAC Name | N-(3,5-dimethoxyphenyl)-1,2-benzothiazol-3-amine |
| InChI | InChI=1S/C15H14N2O2S/c1-18-11-7-10(8-12(9-11)19-2)16-15-13-5-3-4-6-14(13)20-17-15/h3-9H,1-2H3,(H,16,17) |
| SMILES | COC1=CC(=CC(=C1)NC2=NSC3=CC=CC=C32)OC |
| Reference | Y Yu et al. Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia. J Med Chem. 2021 Dec 9;64(23):17384-17402. |
